IL226405A0 - Methods and compounds useful in synthesis@aminodihydrothializin@fused - Google Patents

Methods and compounds useful in synthesis@aminodihydrothializin@fused

Info

Publication number
IL226405A0
IL226405A0 IL226405A IL22640513A IL226405A0 IL 226405 A0 IL226405 A0 IL 226405A0 IL 226405 A IL226405 A IL 226405A IL 22640513 A IL22640513 A IL 22640513A IL 226405 A0 IL226405 A0 IL 226405A0
Authority
IL
Israel
Prior art keywords
synthesis
methods
compounds useful
fused aminodihydrothiazine
aminodihydrothiazine derivatives
Prior art date
Application number
IL226405A
Other languages
English (en)
Hebrew (he)
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IL226405A0 publication Critical patent/IL226405A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL226405A 2011-01-21 2013-05-16 Methods and compounds useful in synthesis@aminodihydrothializin@fused IL226405A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161434849P 2011-01-21 2011-01-21
PCT/US2012/022053 WO2012100179A1 (en) 2011-01-21 2012-01-20 Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives

Publications (1)

Publication Number Publication Date
IL226405A0 true IL226405A0 (en) 2013-07-31

Family

ID=45563570

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226405A IL226405A0 (en) 2011-01-21 2013-05-16 Methods and compounds useful in synthesis@aminodihydrothializin@fused

Country Status (12)

Country Link
US (3) US8426584B2 (cg-RX-API-DMAC7.html)
EP (1) EP2665716B1 (cg-RX-API-DMAC7.html)
JP (2) JP5993875B2 (cg-RX-API-DMAC7.html)
CN (2) CN106632401B (cg-RX-API-DMAC7.html)
BR (1) BR112013016241A2 (cg-RX-API-DMAC7.html)
CA (1) CA2814014A1 (cg-RX-API-DMAC7.html)
ES (1) ES2624288T3 (cg-RX-API-DMAC7.html)
IL (1) IL226405A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013005115A (cg-RX-API-DMAC7.html)
RU (1) RU2013138226A (cg-RX-API-DMAC7.html)
SG (2) SG10201601516QA (cg-RX-API-DMAC7.html)
WO (1) WO2012100179A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
TWI639607B (zh) 2013-06-18 2018-11-01 美國禮來大藥廠 Bace抑制劑
US10117876B2 (en) * 2014-10-10 2018-11-06 Eisai R&D Management Co., Ltd. Pharmaceutical composition of fused aminodihydrothiazine derivative
CA3042020A1 (en) * 2016-10-27 2018-05-03 Eisai R&D Management Co., Ltd. Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
AU2019309938A1 (en) 2018-07-24 2021-03-11 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235551A (en) 1966-02-15 Novel derivatives of
US3227713A (en) 1966-01-04 Azine derivatives
JPH0967355A (ja) 1995-08-31 1997-03-11 Tokyo Tanabe Co Ltd チアジン誘導体、チアゾール誘導体及びそれらの製造方法
KR20020097484A (ko) 2000-05-19 2002-12-31 다케다 야쿠힌 고교 가부시키가이샤 β-씨크리타아제 억제제
US6562783B2 (en) 2001-05-30 2003-05-13 Neurologic, Inc. Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors
AU2003254844A1 (en) 2002-08-09 2004-02-25 Takeda Chemical Industries, Ltd. Substituted amino compounds and use thereof
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
JP2004149429A (ja) 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
EP1562897B1 (en) 2002-11-12 2009-09-16 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
CN102627609B (zh) 2003-12-15 2016-05-04 默沙东公司 杂环天冬氨酰蛋白酶抑制剂
EP1732906A4 (en) 2004-03-30 2007-11-21 Merck & Co Inc 2-AMINOTHIAZONE COMPOUNDS SUITABLE AS ASPARTYL PROTEASE INHIBITORS
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
WO2006041404A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-compounds and uses thereof
WO2006041405A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-pyrimidones and uses thereof
JP2008526999A (ja) 2005-01-19 2008-07-24 メルク エンド カムパニー インコーポレーテッド アルツハイマー病治療用ベータ−セクレターゼインヒビターとして活性な置換へテロ環含有三級カルビナミン
BRPI0612072A2 (pt) 2005-06-14 2010-10-19 Schering Corp inibidores da aspartil protease
AU2006270084B2 (en) 2005-07-18 2011-08-25 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
KR101052122B1 (ko) 2005-10-25 2011-07-26 시오노기세야쿠 가부시키가이샤 아미노디히드로티아진 유도체
US20090099217A1 (en) 2006-04-05 2009-04-16 Astex Therapeutics Ltd. 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies
WO2007139230A1 (ja) 2006-05-31 2007-12-06 Asubio Pharma Co., Ltd. 7員環化合物並びにその製造法および医薬用途
JP2010512389A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
MX2009011498A (es) 2007-04-24 2009-11-10 Shionogi & Co Derivados de aminodihidrotiazina sustituida con un grupo ciclico.
US8193187B2 (en) 2007-05-29 2012-06-05 Santen Pharmaceutical Co., Ltd. 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
US20100317850A1 (en) * 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
MX2011003189A (es) 2008-09-30 2011-04-27 Eisai R&D Man Co Ltd Nuevo derivado de aminodihidrotiazina fusionada.
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
WO2012003274A1 (en) 2010-07-01 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives

Also Published As

Publication number Publication date
US20120190848A1 (en) 2012-07-26
ES2624288T3 (es) 2017-07-13
CN103502231A (zh) 2014-01-08
BR112013016241A2 (pt) 2016-07-12
SG10201601516QA (en) 2016-03-30
US8962858B2 (en) 2015-02-24
SG191710A1 (en) 2013-08-30
CN106632401A (zh) 2017-05-10
JP6087005B2 (ja) 2017-03-01
US8802871B2 (en) 2014-08-12
EP2665716B1 (en) 2017-03-08
JP2014503001A (ja) 2014-02-06
JP5993875B2 (ja) 2016-09-14
CN106632401B (zh) 2020-12-29
RU2013138226A (ru) 2015-02-27
US20130197244A1 (en) 2013-08-01
CA2814014A1 (en) 2012-07-26
US8426584B2 (en) 2013-04-23
EP2665716A1 (en) 2013-11-27
MX2013005115A (es) 2013-06-03
US20140309429A1 (en) 2014-10-16
JP2016121177A (ja) 2016-07-07
WO2012100179A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
IL226405A0 (en) Methods and compounds useful in synthesis@aminodihydrothializin@fused
AP4055A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
IL227252A0 (en) Aminodihydrothiazine history from sisterhood
EP2736330A4 (en) COMPOUNDS AND METHODS
GB201101140D0 (en) Fused aminodihydrothiazine derivatives
SI2683731T1 (sl) C4-monometil triterpenoidni derivati in postopki njihove uporabe
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2747560A4 (en) CONNECTIONS AND METHODS
SG11201400484RA (en) Novel heterocyclic derivatives and their uses
EP2736332A4 (en) CONNECTIONS AND METHODS
EP2736329A4 (en) COMPOUNDS AND METHODS
IL223220A (en) A process for producing the history of extinacidine and its intermediates
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
ZA201305277B (en) Phenyl-isoxazol derivatives and preparation process thereof
IL229968A0 (en) Tetrazolyloxy derivatives and methods for their production
PL2694532T3 (pl) Pochodne aureobasidin i sposoby syntezy
ZA201404277B (en) Process for making magnolol and derivatives thereof
IL234080A0 (en) Tetrazolylhydroxyimino derivatives and methods for their production
SG2014010433A (en) Stable compositions and methods for preparing the same
PL395175A1 (pl) Nowe pochodne dekstrometorfanu i sposób ich wytwarzania
PL395177A1 (pl) Nowe karboamidowe pochodne dekstrometorfanu i sposób ich wytwarzania
GB201100183D0 (en) Fused aminodihydropyrimidone derivatives
PL391303A1 (pl) Nowa pochodna pirymidopirymidyny i sposób wytwarzania nowej pochodnej pirymidopirymidyny
PL391316A1 (pl) Nowa pochodna pirymidopirymidyny i sposób wytwarzania nowej pochodnej pirymidopirymidyny